Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Aug;66(8):2700-2711.
doi: 10.1007/s10620-020-06477-y. Epub 2020 Jul 17.

Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease

Jonathan M Rhodes  1 , Sreedhar Subramanian  2 , Paul K Flanagan  3 , Graham W Horgan  4 , Kate Martin  2 , John Mansfield  5 , Miles Parkes  6 , Ailsa Hart  7 , Helen Dallal  8 , Tariq Iqbal  9 , Jeffrey Butterworth  10 , Kate Culshaw  11 , Christopher Probert  2
Affiliations
Randomized Controlled Trial

Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease

Jonathan M Rhodes et al. Dig Dis Sci. 2021 Aug.

Abstract

Background: Increased mucosa-associated E. coli are present in Crohn's disease, but their role in pathogenesis is uncertain.

Aims: To assess efficacy and safety of an antibiotic/hydroxychloroquine combination effective against E. coli inside macrophages.

Methods: Adults with moderately active disease (CDAI > 220-450 plus C reactive protein ≥ 5 mg/l and/or fecal calprotectin > 250 μg/g) were randomized to receive (open-label) oral budesonide (Entocort CR 9 mg/day 8 weeks, 6 mg/day 2 weeks, 3 mg/day 2 weeks) or oral ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mg tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mg tds for 20 weeks. Primary endpoints were remission (CDAI ≤ 150) at 10 weeks, remission maintained to 24 weeks, and remission maintained to 52 weeks. Patients not responding (CDAI fall by > 70) by 10 weeks were invited to crossover onto the alternative therapy.

Results: Fifty-nine patients were recruited across 8 sites. Including crossover, 39 patients received antibiotics/hydroxychloroquine and 39 received budesonide. At 10 weeks, 24 weeks, and 52 weeks on initial therapy, only 2/27, 2/27, and 1/27 were in remission on antibiotics/hydroxychloroquine compared with 8/32, 1/32, and 1/32 on budesonide (P = 0.092 at 10 weeks). Withdrawals by 10 weeks due to adverse events were seen in 15 receiving antibiotics/hydroxychloroquine and 6 budesonide. Results including crossover were more promising with 9/24 patients receiving antibiotics/hydroxychloroquine per protocol in remission by 24 weeks. No correlation was seen between response to antibiotics/hydroxychloroquine and ASCA/OmpC antibody status or disease location.

Conclusion: Overall results with this antibiotic/hydroxychloroquine combination were unimpressive, but long-term remission is seen in some patients and justifies further study.

Trial registration: ClinicalTrials.gov NCT01783106.

Keywords: Antibiotics; Ciprofloxacin; Crohn’s disease; Doxycycline; E. coli; Hydroxychloroquine.

PubMed Disclaimer

Comment in

References

    1. Palmela C, Chevarin C, Xu Z, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 2018;67:574–587. - DOI
    1. Ryan P, Kelly RG, Lee G, et al. Bacterial DNA within granulomas of patients with Crohn’s disease—detection by laser capture microdissection and PCR. Am J Gastroenterol. 2004;99:1539–1543. - DOI
    1. O’Brien CL, Pavli P, Gordon DM, et al. Detection of bacterial DNA in lymph nodes of Crohn’s disease patients using high throughput sequencing. Gut. 2014;63:1596–1606. - DOI
    1. Gutiérrez A, Zapater P, Juanola O, et al. Gut bacterial DNA translocation is an independent risk factor of flare at short term in patients with Crohn’s disease. Am J Gastroenterol. 2016;111:529–540. - DOI
    1. Keita ÅV, Alkaissi LY, Holm EB, et al. Enhanced E. coli LF82 translocation through follicle-associated epithelium in Crohn’s disease is dependent on long polar fimbriae and CEACAM6-expression, and increases paracellular permeability. J Crohns Colitis. 2020;14:216–229. - DOI

Publication types

MeSH terms

Associated data